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Abstract
Background: The development of CRISPR genome editing has transformed biomedical research. Most applications
reported thus far rely upon the Cas9 protein from Streptococcus pyogenes SF370 (SpyCas9). With many RNA guides,
wildtype SpyCas9 can induce significant levels of unintended mutations at near-cognate sites, necessitating substantial
efforts toward the development of strategies to minimize off-target activity. Although the genome-editing potential of
thousands of other Cas9 orthologs remains largely untapped, it is not known how many will require similarly extensive
engineering to achieve single-site accuracy within large genomes. In addition to its off-targeting propensity, SpyCas9 is
encoded by a relatively large open reading frame, limiting its utility in applications that require size-restricted delivery
strategies such as adeno-associated virus vectors. In contrast, some genome-editing-validated Cas9 orthologs are
considerably smaller and therefore better suited for viral delivery.
Results: Here we show that wildtype NmeCas9, when programmed with guide sequences of the natural length of 24
nucleotides, exhibits a nearly complete absence of unintended editing in human cells, even when targeting sites that
are prone to off-target activity with wildtype SpyCas9. We also validate at least six variant protospacer adjacent motifs
(PAMs), in addition to the preferred consensus PAM (5′-N4GATT-3′), for NmeCas9 genome editing in human cells.
Conclusions: Our results show that NmeCas9 is a naturally high-fidelity genome-editing enzyme and suggest that
additional Cas9 orthologs may prove to exhibit similarly high accuracy, even without extensive engineering.
Keywords: Cas9, CRISPR, sgRNA, Protospacer adjacent motif, Off-target, Neisseria meningitidis
Background
Over the past decade, clustered, regularly interspaced,
short palindromic repeats (CRISPRs) have been revealed
as genomic sources of small RNAs (CRISPR RNAs
(crRNAs)) that specify genetic interference in many bac-
teria and most archaea [1–3]. CRISPR sequences include
“spacers,” which often match sequences of previously en-
countered invasive nucleic acids such as phage genomes
and plasmids. In conjunction with CRISPR-associated
(Cas) proteins, crRNAs recognize target nucleic acids
(DNA, RNA, or both, depending on the system) by base
pairing, leading to their destruction. The primary natural
function of CRISPR-Cas systems is to provide adaptive
immunity against phages [4, 5] and other mobile genetic
elements [6]. CRISPR-Cas systems are divided into two
main classes: class 1, with large, multi-subunit effector
complexes, and class 2, with single-protein-subunit effec-
tors [7]. Both CRISPR-Cas classes include multiple types
based primarily on the identity of a signature effector pro-
tein. Within class 2, the type II systems are the most abun-
dant and the best characterized. The interference function
of type II CRISPR-Cas systems requires the Cas9 protein,
the crRNA, and a separate non-coding RNA known as the
trans-activating crRNA (tracrRNA) [8–10]. Successful
interference also requires that the DNA target (the “proto-
spacer”) be highly complementary to the spacer portion of
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the crRNA and that the PAM consensus be present at
neighboring base pairs [11, 12].
Following the discovery that type II interference oc-
curs via double-strand breaks (DSBs) in the DNA target
[9], the Cas9 protein was shown to be the only Cas pro-
tein required for type II interference, to be manually re-
programmable via engineered CRISPR spacers, and to be
functionally portable between species that diverged
billions of years ago [10]. Biochemical analyses with
purified Cas9 confirmed its role as a crRNA-guided,
programmable nuclease that induces R-loop formation
between the crRNA and one dsDNA strand, and that
cleaves the crRNA-complementary and noncomple-
mentary strands with its HNH and RuvC domains, re-
spectively [13, 14]. In vitro cleavage reactions also
showed that the tracrRNA is essential for DNA cleav-
age activity and that the naturally separate crRNA
and tracrRNA could retain function when fused into
a single-guide RNA (sgRNA) [14]. Several independent re-
ports then showed that the established DSB-inducing ac-
tivity of Cas9 could be elicited not only in vitro but also in
living cells, both bacterial [15] and eukaryotic [16–20]. As
with earlier DSB-inducing systems [21], cellular repair of
Cas9-generated DSBs by either non-homologous end join-
ing (NHEJ) or homology-directed repair (HDR) enabled
live-cell targeted mutagenesis, and the CRISPR-Cas9 sys-
tem has now been widely adopted as a facile genome-edit-
ing platform in a wide range of organisms [22–24]. In
addition to genome editing, catalytically inactivated Cas9
(“dead” Cas9, dCas9) retains its sgRNA-guided DNA bind-
ing function, enabling fused or tethered functionalities to
be delivered to precise genomic loci [25, 26]. Similar
RNA-guided tools for genome manipulations have since
been developed from type V CRISPR-Cas systems that use
the Cas12a (formerly Cpf1) enzyme [27].
Type II CRISPR-Cas systems are currently grouped
into three subtypes (II-A, II-B, and II-C) [7, 28]. The vast
majority of Cas9 characterization has been done on a single
type II-A ortholog, SpyCas9, in part due to its consistently
high genome-editing activity. SpyCas9’s sgRNAs typically
contain a 20-nt guide sequence (the spacer-derived se-
quence that base pairs to the DNA target [8, 14]). The
PAM requirement for SpyCas9 is 5′-NGG-3′ (or, less favor-
ably, 5′-NAG-3′), after the 3′ end of the protospacer’s
crRNA-noncomplementary strand [8, 14]. Based on these
and other parameters, many sgRNAs directed against po-
tentially targetable sites in a large eukaryotic genome also
have near-cognate sites available to it that lead to unin-
tended, “off-target” editing. Indeed, off-target activity by
SpyCas9 has been well-documented with many sgRNA-tar-
get combinations [29, 30], prompting the development of
numerous approaches to limit editing activity at unwanted
sites [31–36]. Although these strategies have been shown to
minimize off-targeting to various degrees, they do not
always abolish it and they can also reduce on-target ac-
tivity, at least with some sgRNAs. Furthermore, each of
these approaches has required extensive testing, valid-
ation, and optimization and in some cases [33, 37, 38]
depended heavily upon prior high-resolution structural
characterization [39–42].
Thousands of other Cas9 orthologs have been docu-
mented [7, 28, 43, 44], providing tremendous untapped
potential for additional genome-editing capabilities be-
yond those offered by SpyCas9. Many Cas9 orthologs
will provide distinct PAM specificities, increasing the
number of targetable sites in any given genome. Many
pair-wise Cas9 combinations also have orthogonal guides
that load into one ortholog but not the other, facilitating
multiplexed applications [44–46]. Finally, some Cas9
orthologs (especially those from subtype II-C) are hun-
dreds of amino acids smaller than the 1368 amino acid
SpyCas9 [7, 43, 44] and are therefore more amenable to
combined Cas9/sgRNA delivery via a single-size-restricted
vector such as adeno-associated virus (AAV) [47, 48]. Fi-
nally, there may be Cas9 orthologs that exhibit additional
advantages such as greater efficiency, natural hyper-accur-
acy, distinct activities, reduced immunogenicity, or novel
means of control over editing. Deeper exploration of the
Cas9 population could therefore enable expanded or im-
proved genome engineering capabilities.
We have used N. meningitidis (strain 8013) as a model
system for the interference functions and mechanisms of
type II-C CRISPR-Cas systems [49–52]. In addition, we
and others previously reported that the type II-C Cas9
ortholog from N. meningitidis (NmeCas9) can be applied
as a genome engineering platform [46, 53, 54]. At 1082
amino acids, NmeCas9 is 286 residues smaller than Spy-
Cas9, making it nearly as compact as SauCas9 (1053
amino acids) and well within range of all-in-one AAV
delivery. Its spacer-derived guide sequences are longer
(24 nt) than those of most other Cas9 orthologs [51],
and like SpyCas9, it cleaves both DNA strands between
the third and fourth nucleotides of the protospacer
(counting from the PAM-proximal end). NmeCas9 also
has a longer PAM consensus (5′-N4GATT-3′, after the
3′ end of the protospacer’s crRNA-noncomplementary
strand) [44, 46, 51–54], leading to a lower density of tar-
getable sites compared to SpyCas9. Considerable vari-
ation from this consensus is permitted during bacterial
interference [46, 52], and a smaller number of variant
PAMs can also support targeting in mammalian cells
[53, 54]. Unlike SpyCas9, NmeCas9 has been found to
cleave the DNA strand of RNA-DNA hybrid duplexes in
a PAM-independent fashion [52, 55] and can also
catalyze PAM-independent, spacer-directed cleavage of
RNA [56]. Recently, natural Cas9 inhibitors (encoded by
bacterial mobile elements) have been identified and vali-
dated in N. meningitidis and other bacteria with type II-C
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systems, providing for genetically encodable off-switches
for NmeCas9 genome editing [57, 58]. These “anti-CRISPR”
(Acr) proteins [59] enable temporal, spatial, or conditional
control over the NmeCas9 system. Natural inhibitors of
type II-A systems have also been discovered in Listeria
monocytogenes [60] and Streptococcus thermophilus [61],
some of which are effective at inhibiting SpyCas9.
The longer PAM consensus, longer guide sequence, or
enzymological properties of NmeCas9 could result in a
reduced propensity for off-targeting, and targeted deep
sequencing at bioinformatically predicted near-cognate
sites is consistent with this possibility [54]. A high de-
gree of genome-wide specificity has also been noted for
the dNmeCas9 platform [62]. However, the true, un-
biased accuracy of NmeCas9 is not known, since empir-
ical assessments of genome-wide off-target editing
activity (independent of bioinformatics prediction) have
not been reported for this ortholog. Here we define and
confirm many of the parameters of NmeCas9 editing
activity in mammalian cells including PAM sequence
preferences, guide length limitations, and off-target
profiles. Most notably, we use two empirical approaches
(GUIDE-seq [63] and SITE-Seq™ [64]) to define Nme-
Cas9 off-target profiles and find that NmeCas9 is a
high-fidelity genome-editing platform in mammalian
cells, with far lower levels of off-targeting than SpyCas9.
These results further validate NmeCas9 as a genome en-
gineering platform and suggest that continued exploration
of Cas9 orthologs could identify additional RNA-guided
nucleases that exhibit favorable properties, even without
the extensive engineering efforts that have been applied to
SpyCas9 [31, 34, 35].
Results
Co-expressed sgRNA increases NmeCas9 accumulation in
mammalian cells
Previously, we demonstrated that NmeCas9 (derived
from N. meningitidis strain 8013 [51]) can efficiently edit
chromosomal loci in human stem cells using either dual
RNAs (crRNA + tracrRNA) or a sgRNA [53]. To further
define the efficacy and requirements of NmeCas9 in
mammalian cells, we first constructed an all-in-one plas-
mid (pEJS15) that delivers both NmeCas9 protein and a
sgRNA in a single transfection vector, similar to our previ-
ous all-in-one dual-RNA plasmid (pSimple-Cas9-Tracr-
crRNA; Addgene #47868) [53]. The pEJS15 plasmid ex-
presses NmeCas9 fused to a C-terminal single-HA epitope
tag and nuclear localization signal (NLS) sequences at
both N- and C-termini under the control of the elongation
factor-1α (EF1α) promoter. The sgRNA cassette (driven
by the U6 promoter) includes two BsmBI restriction sites
that are used to clone a spacer of interest from short, syn-
thetic oligonucleotide duplexes. First, we cloned three dif-
ferent bacterial spacers (spacers 9, 24, and 25) from the
endogenous N. meningitidis CRISPR locus (strain 8013)
[51, 52] to express sgRNAs that target protospacer (ps) 9,
ps24 or ps25, respectively (Additional file 1: Figure S1A).
None of these protospacers have cognate targets in the
human genome. We also cloned a spacer sequence to
target an endogenous genomic NmeCas9 target site
(NTS) from chromosome 10 that we called NTS3
(Table 1). Two of the resulting all-in-one plasmids (spa-
cer9/sgRNA and NTS3/sgRNA), as well as a plasmid
lacking the sgRNA cassette, were transiently transfected
into HEK293T cells for 48 h, and NmeCas9 expression
was assessed by anti-HA western blot (Fig. 1a). As a
positive control, we also included a sample transfected
with a SpyCas9-expressing plasmid (triple-HA epitope-
tagged, and driven by the cytomegalovirus (CMV) pro-
moter) [65] (Addgene #69220). Full-length NmeCas9 was
efficiently expressed in the presence of both sgRNAs
(lanes 3 and 4). However, the abundance of the protein
was much lower in the absence of sgRNA (lane 2). A dif-
ferent type II-C Cas9 (Corynebacterium diphtheria Cas9,
CdiCas9) was shown to be dramatically stabilized by its
cognate sgRNA when subjected to proteolysis in vitro
[55]; if similar resistance to proteolysis occurs with
NmeCas9 upon sgRNA binding, it could explain some
or all of the sgRNA-dependent increase in cellular
accumulation.
Efficient editing in mammalian cells by NmeCas9
To establish an efficient test system for NmeCas9 activity
in mammalian cells, we used a co-transfected fluorescent
reporter carrying two truncated, partially overlapping GFP
fragments that are separated by a cloning site [66] into
which we can insert target protospacers for NmeCas9
(Additional file 1: Figure S1B). Cleavage promotes a
single-strand-annealing-based repair pathway that gener-
ates an intact GFP open reading frame (ORF), leading to
fluorescence [66] that can be scored after 48 h by flow cy-
tometry. We generated reporters carrying three validated
bacterial protospacers (ps9, ps24, and ps25, as described
above) [51, 52] for transient cotransfection into HEK293T
cells along with the corresponding NmeCas9/sgRNA con-
structs. Figure 1b shows that all three natural protospacers
of NmeCas9 can be edited in human cells and the effi-
ciency of GFP induction was comparable to that observed
with SpyCas9 (Fig. 1b).
Next, we reprogrammed NmeCas9 by replacing the bac-
terially derived spacers with a series of spacers designed to
target 13 human chromosomal sites (Fig. 1c, d and e) with
an N4GATT PAM (Table 1). These sgRNAs induced in-
sertion/deletion (indel) mutations at all sites tested, except
NTS10 (Fig. 1c, lanes 23–25), as determined by T7 Endo-
nuclease 1 (T7E1) digestion (Fig. 1c). The editing efficien-
cies ranged from 5% for NTS1B site to 47% in the case of
NTS33 (Fig. 1d), though T7E1 tends to underestimate the
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Table 1 NmeCas9 or SpyCas9 guide and target sequences used in this study. NTS, NmeCas9 target site; STS, SpyCas9 target site. The
sgRNA spacer sequences (5′➔3′) are shown with their canonical lengths, and with a 5′-terminal G residue; non-canonical lengths are
described in the text and figures. Target site sequences are also 5′➔3′ and correspond to the DNA strand that is non-complementary to
the sgRNA, with PAM sequences underlined. The names of sites that showed at least 3% editing with NmeCas9 are indicated in bold
NmeCas9 Site Gene or locus Spacer Sequence Target site, with PAM
Ps9 N.A. (reporter) GCAUCCUCAGAUUUAGUAUUCAGA ATGACATCCTCAGATTTAGTATTCAGAATATGATTTTC
Ps24 N.A. (reporter) GUCGCGCAACAAAACCCCGCUACU GTCGTCGCGCAACAAAACCCCGCTACTCGGCGATTTTC
Ps25 N.A. (reporter) GCAUGCGCGGCGCAUUACCUUUAC TCCTCATGCGCGGCGCATTACCTTTACGCCGGATTGCC
NTS1B SLC9A9 GGGCAUCAUGAUUUUGAACUCCCU CCTTGGCATCATGATTTTGAACTCCCTATGTGATTCTA
NTS1C SLC9A9 GUGGUCUGGGGUACAGCCUUGGCA TACTUGGTCTGGGGTACAGCCTTGGCATCATGATTTTG
NTS1C-OT1 PHKG2 GCGGUGUGAGGUACAGCCUUGGCA TAATCGGTGTGAGGTACAGCCTTGGCATCAGGATTTCT
NTS3 AL158836 GAUGCUCAGAAAGAGGAAGCUGGU GGGGATGCTCAGAAAGAGGAAGCTGGTTTATGATTGGA
NTS4B FLJ00328 GGACAGGAGUCGCCAGAGGCCGGU GCAGGACAGGAGTCGCCAGAGGCCGGTGGTGGATTTCC
NTS4C FLJ00328 GGGGCUGGCUCCACGUCGCGCCGC TGCGGGGCTGGCTCCACGTCGCGCCGCGGCGGTTTGGG
NTS5 AF064860 GAAACAGACUCGCAAGACUUCAGA GACAAAACAGACTCGCAAGACTTCAGATACAGATTCCA
NTS7 LOC100505797 GAGGGAGAGAGGUGAGCGGAUGAA GCAAAGGGAGAGAGGTGAGCGGATGAAGGGAGATTGGT
NTS8 ESPN GGACGCAAUUCCAGAGGUGAUGGG CGGCGACGCAATTCCAGAGGTGATGGGGAGTGATTGTC
NTS9 ZNHIT2 GGCGCUGUGUUUUCGCAAAGCUUC CGGCGCGCTGTGTTTTCGCAAAGCTTCCGAGGATTCTC
NTS10 HHLA1 GCAGCCAAGUUUGAGAACUGCUGU TGTGCAGCCAAGTTTGAGAACTGCTGTTACAGATTTCC
NTS11 SMARCB1 GUUCCAGUUGGGAAGGGCCAGUGC TAGATTCCAGTTGGGAAGGGCCAGTGCCTCCGATTCCA
NTS20 CH251-396E2 GAUACCAGUCAGAUUUGUGCAAUG TCTAATACCAGTCAGATTTGTGCAATGTTGGGTTTGGA
NTS21 TNNC1 GCCAGAGCUGCCGCCAGACAGUGA CAGTCCAGAGCTGCCGCCAGACAGTGATGCTGTCTTGG
NTS22 ANO1 GUUUGGCUGGGCGCUCCUGAAACU TGCTTTTGGCTGGGCGCTCCTGAAACTCTGGGCTTTCA
NTS23 LOC103240889 GCGGCCCCGGGGCCGGGCCGCGGG GCGACGGCCCCGGGGCCGGGCCGCGGGCGGAGACTGAC
NTS24 AC097382 GCUGCCUCAUGGUGUGUGCUGAGG GCTGCTGCCTCATGGTGTGTGCTGAGGCTCAGACATCA
NTS25 AC193513 GGUUUCUCAUCCUGUCUUCUGCCU CCGCGTTTCTCATCCTGTCTTCTGCCTAGTGGATATGT
NTS26 LOC105378512 GUUCAAAAGUAGCGGGCGCUAGGC GTACTTCAAAAGTAGCGGGCGCTAGGCGGGTGTTTCTG
NTS27 TIE1 GUUCUCCAAGCCCUCGGACCUCGU CGGCTTCTCCAAGCCCTCGGACCTCGTGGGCGTCTTCT
NTS28 AL138885 GCAGGGGCAGGGGCGCAUCAGCUG GCGGCAGGGGCAGGGGCGCATCAGCTGTCCGGCTTGGA
NTS30 NEK8 GGGGCUCCGGAGCCCACCCCAGGA CGCGGGGCTCCGGAGCCCACCCCAGGACCAGGACTTAG
NTS31 POC1A GUGGGAAGUGUAGCUCCACCUUCC ATGTTGGGAAGTGTAGCTCCACCTTCCTCCAGACATAG
NTS32 VEGFA GCCCCGGCUCUGGCUAAAGAGGGA CACACCCCGGCTCTGGCTAAAGAGGGAATGGGCTTTGG
NTS33 VEGFA GCGGGGAGAAGGCCAGGGGUCACU GGAGCGGGGAGAAGGCCAGGGGTCACTCCAGGATTCCA
NTS55 CYBB GCUGGAUUACUGUGUGGUAGAGGG CTAGCTGGATTACTGTGTGGTAGAGGGAGGTGATTAGC
NTS58 AAVS1 GUUUGCCUGGACACCCCGUUCUCC TTTCTTTGCCTGGACACCCCGTTCTCCTGTGGATTCGG
NTS59 AAVS1 GACCCCACAGUGGGGCCACUAGGG CTCCACCCCACAGTGGGGCCACTAGGGACAGGATTGGT
NTS63 AAVS1 GAGUUAGAACUCAGGACCAACUUA CCAAAGTTAGAACTCAGGACCAACTTATTCTGATTTTG
NTS64 Rosa26 GGCAGAUCACGAGGGAAGAGGGGG AGTTGCAGATCACGAGGGAAGAGGGGGAAGGGATTCTC
DTS1-NmeCas9 KL GCUGGCUGAGCCCAUUUUCGGCUC CTGGCTGGCTGAGCCCATTTTCGGCTCTGGAGATTATC
DTS3-NmeCas9 ARHGEF9 GACUGAAGGCGAGGUCCGGGGCGG ACTGACTGAAGGCGAGGTCCGGGGCGGAGGGGATTGGG
DTS7-NmeCas9 LSP1 GGCUGGCACCCUCCAUGUACCCAG GCCGGCTGGCACCCTCCATGTACCCAGGGGAGATTCCA
DTS8-NmeCas9 PCDHB4 GUGAGUGAAGAUAUGAUAAGUUCU CTGGTGAGTGAAGATATGATAAGTTCTGGGGGATTGTC
SpyCas9 Site Gene or locus Spacer Sequence Target site, with PAM
STS60 AAVS1 GUUAAUGUGGCUCUGGUUCU CCGGTTAATGTGGCTCTGGTTCTGGGTAC
STS61 AAVS1 GUCCCCUCCACCCCACAGUG TCTGTCCCCTCCACCCCACAGTGGGGCCA
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true frequencies of indel formation [67]. Targeted deep se-
quencing of PCR amplicons, which is a more quantitative
readout of editing efficiency, confirmed editing with indel
efficiencies ranging from ~ 15 to 85% (Fig. 1e). These re-
sults show that NmeCas9 can induce, with variable effi-
ciency, edits at many genomic target sites in human cells.
Furthermore, we demonstrated NmeCas9 genome editing
in multiple cell lines and via distinct delivery modes.
Nucleofection of NmeCas9 ribonucleoprotein (RNP)
(loaded with an in vitro-transcribed sgRNA) led to indel
formation at three sites in K562 chronic myelogenous
leukemia cells and in hTERT-immortalized human fore-
skin fibroblasts (gift from Dr. Job Dekker) (Fig. 1f). In
addition, mouse embryonic stem cells (mESCs) and
HEK293T cells were transduced with a lentivirus con-
struct expressing NmeCas9. In these cells, transient trans-
fection of plasmids expressing a sgRNA led to genome
editing (Fig. 1f). Collectively, our results show that Nme-
Cas9 can be used for genome editing in a range of human
or mouse cell lines via plasmid transfection, RNP delivery,
or lentiviral transduction.
PAM specificity of NmeCas9 in human cells
During native CRISPR interference in bacterial cells,
considerable variation in the N4GATT PAM consensus
is tolerated: although the G1 residue (N4GATT) is
strictly required, virtually all other single mutations at
A2 (N4GATT), T3 (N4GATT), and T4 (N4GATT) retain
at least partial function in licensing bacterial interference
[46, 52]. In contrast, fewer NmeCas9 PAM variants have
been validated for genome editing in mammalian cells
[53, 54]. To gain more insight into NmeCas9 PAM flexi-
bility and specificity in mammalian cells, and in the con-
text of an otherwise identical target site and an invariant
sgRNA, we employed the split-GFP readout of cleavage
activity (Additional file 1: Figure S1B). We introduced
single-nucleotide mutations at every position of the
PAM sequence of ps9, as well as all double-mutant com-
binations of the four most permissive single mutants,
and then measured the ability of NmeCas9 to induce
GFP fluorescence in transfected HEK293T cells. The results
are shown in Fig. 2a. As expected, mutation of the G1 resi-
due to any other base reduced editing to background levels,
as defined by the control reporter that lacks a protospa-
cer [(no ps), see Fig. 3a]. As for mutations at the A2,
T3, and T4 positions, four single mutants (N4GCTT,
N4GTTT, N4GACT, and N4GATA) and two double mu-
tants (N4GTCT and N4GACA) were edited with effi-
ciencies approaching that observed with the N4GATT
PAM. Two other single mutants (N4GAGTand N4GATG)
and three double mutants (N4GCCT, N4GCTA, and
N4GTTA) gave intermediate or low efficiencies, and the
remaining mutants tested were at or near background
levels. We note that some of the minimally functional or
non-functional PAMs (e.g., N4GAAT and N4GATC) in
this mammalian assay fit the functional consensus se-
quences defined previously in E. coli [46].
We then used T7E1 analysis to validate genome edit-
ing at eight native chromosomal sites associated with
the most active PAM variants (N4GCTT, N4GTTT,
N4GACT, N4GATA, N4GTCT, and N4GACA). Our re-
sults with this set of targets indicate that all of these
PAM variants tested except N4GACA support chromo-
somal editing (Fig. 2b and c). Targeted deep sequencing
confirmed editing with indel efficiencies ranging from ~
8 to 60% (except for target site NTS21, which amplified
poorly with Illumina-compatible primers) (Fig. 2d).
Apo NmeCas9 is not genotoxic to mammalian cells
NmeCas9 and several other type II-C Cas9 orthologs
have been shown to possess an RNA-dependent ssDNA
cleavage (DNase H) activity in vitro [52, 55]. R-loops (re-
gions where an RNA strand invades a DNA duplex to
form a DNA:RNA hybrid, with the other DNA strand
displaced) occur naturally during transcription and other
cellular processes [68]. Since DNase H activity is inde-
pendent of the tracrRNA or the PAM sequence, it is
theoretically possible that it could degrade naturally oc-
curring R-loops in living cells. Global degradation of
R-loops in cells could result in an increase in DNA
damage detectable by increased γH2AX staining [69].
To test whether the DNase H activity of NmeCas9 could
Table 1 NmeCas9 or SpyCas9 guide and target sequences used in this study. NTS, NmeCas9 target site; STS, SpyCas9 target site. The
sgRNA spacer sequences (5′➔3′) are shown with their canonical lengths, and with a 5′-terminal G residue; non-canonical lengths are
described in the text and figures. Target site sequences are also 5′➔3′ and correspond to the DNA strand that is non-complementary to
the sgRNA, with PAM sequences underlined. The names of sites that showed at least 3% editing with NmeCas9 are indicated in bold
(Continued)
NmeCas9 Site Gene or locus Spacer Sequence Target site, with PAM
STS62 AAVS1 GGGGCCACUAGGGACAGGAU AGTGGGGCCACTAGGGACAGGATTGGTGA
DTS1-SpyCas9 KL GCUGAGCCCAUUUUCGGCUC CTGGCTGAGCCCATTTTCGGCTCTGGAGA
DTS3-SpyCas9 ARHGEF9 GAAGGCGAGGUCCGGGGCGG ACTGAAGGCGAGGTCCGGGGCGGAGGGGA
DTS7-SpyCas9 LSP1 GGCACCCUCCAUGUACCCAG GCTGGCACCCTCCATGTACCCAGGGGAGA
DTS8-SpyCas9 PCDHB4 GUGAAGAUAUGAUAAGUUCU TGAGTGAAGATATGATAAGTTCTGGGGGA
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Fig. 1 NmeCas9 expression and activity in human (HEK293T) cells. a Western blot detection of HA-tagged NmeCas9 in transiently transfected
HEK293T cells. Lane 1: cells transfected with SpyCas9 plasmid under the control of the CMV promoter. Lane 2: cells transfected with NmeCas9
plasmid under the control of the elongation factor-1α (EF1α) promoter. Lane 3: cells expressing NmeCas9 and a non-targeting sgRNA (nt-sgRNA),
which lacks a complementary site in the human genome. Lane 4: cells expressing NmeCas9 and a sgRNA targeting chromosomal site NTS3. Upper panel:
anti-HA western blot. Lower panel: anti-GAPDH western blot as a loading control. b NmeCas9 targeting co-transfected split-GFP reporter with ps9, ps24,
and ps25 sites. Plasmid cleavage by SpyCas9 is used as a positive control, and a reporter without a guide-complementary site (No ps: no protospacer) is
used as a negative control to define background levels of recombination leading to GFP+ cells. c NmeCas9 programmed independently with different
sgRNAs targeting eleven genomic sites flanked by an N4GATT PAM, detected by T7E1 analysis. Products resulting from NmeCas9 genome editing are
denoted by the red dots. d Quantitation of editing efficiencies from three independent biological replicates performed on different days. Error bars
indicate ± standard error of the mean (± s.e.m.). e Editing efficiencies for chromosomal target sites as measured by PCR and high-throughput sequencing
(Deep sequencing). Data are mean values ± s.e.m. from three biological replicates performed on different days. f Genomic edits with NmeCas9
programmed independently with different guides in different cell lines and using different methods of delivery
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lead to an increase in γH2AX, we transduced mouse em-
bryonic stem cells E14 (mESCs) with lentiviral plasmids
expressing NmeCas9 (Addgene #120076) and dNmeCas9
(Addgene #120077) (which lacks DNase H activity [52]) to
create stable cell lines expressing NmeCas9 or dNmeCas9,
respectively. mESCs are ideal for this purpose as R-loops
have been extensively studied in these cells and have been
shown to be important for differentiation [70]. We per-
formed γH2AX staining of these two cell lines and com-
pared them to wildtype E14 cells. As a positive control for
γH2AX induction, we exposed wildtype E14 cells to UV, a
known stimulator of the global DNA damage response.
Immunofluorescence microscopy of cells expressing Nme-
Cas9 or dNmeCas9 exhibited no increase in γH2AX foci
compared to wildtype E14, suggesting that sustained
NmeCas9 expression is not genotoxic (Additional file 1:
Figure S2A). In contrast, cells exposed to UV light
showed a significant increase in γH2AX levels. Flow cy-
tometric measurements of γH2AX immunostaining con-
firmed these results (Additional file 1: Figure S2B). We
next tested whether continuous NmeCas9 expression in
human HEK293T cells has genotoxic effects. We per-
formed γH2AX staining as above and found no difference
between the wildtype cells and those expressing NmeCas9
Fig. 2 Characterization of functional PAM sequences in human (HEK293T) cells. a Split-GFP activity profile of NmeCas9 cleavage with ps9 sgRNA,
with the target site flanked by different PAM sequences. Bars represent mean values ± s.e.m. from three independent biological replicates
performed on different days. b T7E1 analysis of editing efficiencies at seven genomic sites flanked by PAM variants, as indicated. Products
resulting from NmeCas9 genome editing are denoted by the red dots. c Editing efficiencies for chromosomal target sites with different PAM
variants, as in B and C, as measured by deep sequencing analysis. d Quantitation of data from (b), as well as an additional site (NTS31;
N4GACA PAM) that was not successfully edited. Bars represent mean values ± s.e.m. from three independent biological replicates performed
on different days
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(Additional file 1: Figure S2C). These data indicate that
NmeCas9 expression does not lead to a global DNA dam-
age response in mESCs or human cells.
Comparative analysis of NmeCas9 and SpyCas9
SpyCas9 is by far the best-characterized Cas9 ortholog
and is therefore the most informative benchmark when
Fig. 3 NmeCas9 and SpyCas9 have comparable editing efficiencies in human (HEK293T) cells when targeting the same chromosomal sites. a Western
blot analysis of NmeCas9 and SpyCas9. HEK293T cells were transfected with the indicated Cas9 ortholog cloned in the same plasmid backbone and
fused to the same HA epitope tags and NLSs. Top panel: anti-HA western blot (EP, empty sgRNA plasmid). Bottom panel: anti-GAPDH western blot,
used as a loading control. Mobilities of protein markers are indicated. b T7E1 analysis of three previously validated SpyCas9 guides targeting the AAVS1
locus, in comparison with NmeCas9 guides targeting nearby AAVS1 sites (mean ± s.e.m., n = 3). c Representative T7EI analyses comparing editing
efficiencies at the dual target sites DTS1, DTS3, DTS7, DTS8, and NTS7, using the indicated Cas9/sgRNA combinations. Products resulting from Cas9
genome editing are denoted by the red dots. d Quantitation of data from (c) (mean ± s.e.m., n = 3). Two-tailed paired Student’s T test showed
significant difference between NmeCas9 and SpyCas9 editing of DTS1, DTS3, and DTS8 (p < 0.05)
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defining the efficiency and accuracy of other Cas9s. To
facilitate comparative experiments between NmeCas9
and SpyCas9, we developed a matched Cas9 + sgRNA
expression system for the two orthologs. This serves to
minimize the expression differences between the two
Cas9s in our comparative experiments, beyond those dif-
ferences dictated by the sequence variations between the
orthologs themselves. To this end, we employed the
separate pCSDest2-SpyCas9-NLS-3XHA-NLS (Addgene
#69220) and pLKO.1-puro-U6sgRNA-BfuA1 (Addgene
#52628) plasmids reported previously for the expression
of SpyCas9 (driven by the CMV promoter) and its sgRNA
(driven by the U6 promoter), respectively [58, 65]. We
then replaced the bacterially derived SpyCas9 sequence
(i.e., not including the terminal fusions) with that of Nme-
Cas9 in the CMV-driven expression plasmid. This yielded
an NmeCas9 expression vector (pEJS424) that is identical
to that of the SpyCas9 expression vector in every way
(backbone, promoters, UTRs, poly(A) signals, terminal fu-
sions, etc.) except for the Cas9 sequence itself. Similarly,
we replaced the SpyCas9 sgRNA cassette in pLKO.1--
puro-U6sgRNA-BfuA1 with that of the NmeCas9
sgRNA [46, 53], yielding the NmeCas9 sgRNA expres-
sion plasmid pEJS333. This matched system facilitates
direct comparisons of the two enzymes’ accumulation
and activity during editing experiments. To assess rela-
tive expression levels of the identically tagged Cas9
orthologs, the two plasmids were transiently transfected
into HEK293T cells for 48 h, and the expression of the
two proteins was monitored by anti-HA western blot
(Fig. 3a). Consistent with our previous data (Fig. 1a),
analyses of samples from identically transfected cells
show that NmeCas9 accumulation is stronger when
co-expressed with its cognate sgRNA (Fig. 3a, compare
lane 6 to 4 and 5), whereas SpyCas9 is not affected by
the presence of its sgRNA (lanes 1–3).
For an initial comparison of the cleavage efficiencies of
the two Cas9s, we chose three previously validated
SpyCas9 guides targeting the AAVS1 “safe harbor” locus
[20, 71] and used the CRISPRseek package [72] to de-
sign three NmeCas9 guides targeting the same locus
within a region of ~ 700 base pairs (Additional file 1:
Figure S3A). The matched Cas9/sgRNA expression sys-
tems described above were used for transient transfec-
tion of HEK293T cells. T7E1 analysis showed that the
editing efficiencies were comparable, with the highest effi-
ciency being observed when targeting the NTS59 site with
NmeCas9 (Fig. 3b and Additional file 1: Figure S3B).
To provide a direct comparison of editing efficiency
between the SpyCas9 and NmeCas9 systems, we took
advantage of the non-overlapping PAMs of SpyCas9 and
NmeCas9 (NGG and N4GATT, respectively). Because
the optimal SpyCas9 and NmeCas9 PAMs are non-over-
lapping, it is simple to identify chromosomal target sites
that are compatible with both orthologs, i.e., that are
dual target sites (DTSs) with a composite PAM sequence
of NGGNGATT that is preferred by both nucleases. In
this sequence context, both Cas9s will cleave the exact
same internucleotide bond (NN/NNNNGGNGATT;
cleaved junction in bold, and PAM region underlined),
and both Cas9s will have to contend with the exact
same sequence and chromatin structural context. Fur-
thermore, if the target site contains a G residue at pos-
ition − 24 of the sgRNA-noncomplementary strand
(relative to the PAM) and another at position − 20, then
the U6 promoter can be used to express perfectly
matched sgRNAs for both Cas9 orthologs. Four DTSs
with these characteristics were used in this comparison
(Additional file 1: Figure S4A). We had previously used
NmeCas9 to target a site (NTS7) that happened also to
match the SpyCas9 PAM consensus, so we included it
in our comparative analysis as a fifth site, even though it
has a predicted rG-dT wobble pair at position − 24 for the
NmeCas9 sgRNA (Additional file 1: Figure S4A).
We compared the editing activities of both Cas9
orthologs programmed to target the five chromosomal
sites depicted in Additional file 1: Figure S4A, initially
via T7E1 digestion. SpyCas9 was more efficient than
NmeCas9 at generating edits at the DTS1 and DTS8
sites (Fig. 3c, lanes 1–2 and 13–14). In contrast, Nme-
Cas9 was more efficient than SpyCas9 at the DTS3 and
NTS7 sites (Fig. 3c, lanes 5–6 and 17–18). Editing at
DTS7 was approximately equal with both orthologs
(Fig. 3c, lanes 9–10). Data from three biological repli-
cates of all five target sites are plotted in Fig. 3d. The re-
mainder of our comparative studies focused on DTS3,
DTS7, and DTS8, as they provided examples of target
sites with NmeCas9 editing efficiencies that are greater
than, equal to, or lower than those of SpyCas9, respect-
ively. The editing efficiency of these three sites was con-
firmed by targeted deep sequencing (see below). At all
three of these sites, the addition of an extra 5′-terminal
G residue had little to no effect on editing by either
SpyCas9 or NmeCas9 (Additional file 1: Figure S4B).
Truncation of the three NmeCas9 guides down to 20
nucleotides (all perfectly matched) again had differential
effects on editing efficiency from one site to the next,
with no reduction in DTS7 editing, partial reduction in
DTS3 editing, and complete loss of DTS8 editing
(Additional file 1: Figure S4B). These results establish
the guide/target context for deeper comparative ana-
lyses of SpyCas9 and NmeCas9 indel spectra and ac-
curacy at shared chromosomal sites.
Indel spectrum at NmeCas9- and SpyCas9-edited sites
Our targeted deep sequencing data at the three dual tar-
get sites DTS3, DTS7 and DTS8 (Fig. 4d, Additional file 1:
Figure S4A and Additional file 2: Table S5) enabled us to
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analyze the spectrum of insertions and deletions gener-
ated by NmeCas9, in comparison with those of SpyCas9
when editing the exact same sites (Additional file 1:
Figures S5B–S8). Although small deletions predomi-
nated at all three sites with both Cas9 orthologs, the fre-
quency of insertions was lower for NmeCas9 than it was
with SpyCas9 (Additional file 1: Figures S5B–S8). For
both SpyCas9 and NmeCas9, the vast majority of inser-
tions were only a single nucleotide (Additional file 1:
Figure S7). The sizes of the deletions varied from one
target site to the other for both Cas9 orthologs. Our data
suggest that at Cas9 edits, deletions predominated over
insertions and the indel size varies considerably from
site to site (Additional file 1: Figures S5B, S9 and S10).
Assessing the genome-wide precision of NmeCas9 editing
All Cas9 orthologs described to date have some propen-
sity to edit off-target sites lacking perfect complementar-
ity to the programmed guide RNA, and considerable
effort has been devoted to developing strategies (mostly
with SpyCas9) to increase editing specificity (reviewed in
[31, 34, 35]). In comparison with SpyCas9, orthologs
such as NmeCas9 that employ longer guide sequences
and that require longer PAMs have the potential for
Fig. 4 Bioinformatic and empirical comparison of NmeCas9 and SpyCas9 off-target sites within the human genome. a Genome-wide computational
(CRISPRseek) predictions of off-target sites for NmeCas9 (with N4GN3 PAMs) and SpyCas9 (with NGG, NGA, and NAG PAMs) with DTS3, DTS7, and DTS8
sgRNAs. Predicted off-target sites were binned based on the number of mismatches (up to six) with the guide sequences. b GUIDE-Seq analysis of
off-target sites in HEK293T cells with sgRNAs targeting DTS3, DTS7, and DTS8, using either SpyCas9 or NmeCas9, and with up to 6 mismatches to the
sgRNAs. The numbers of detected off-target sites are indicated at the top of each bar. c Numbers of independent GUIDE-Seq reads for the on- and
off-target sites for all six Cas9/sgRNA combinations from (b) (SpyCas9, orange; NmeCas9, blue), binned by the number of mismatches with the
corresponding guide. d Targeted deep sequencing analysis of editing efficiencies at on- and off-target sites from (a) or (b) with SpyCas9 (left, orange)
or NmeCas9 (right, blue). Data for off-target sites are in grey. For SpyCas9, all off-target sites were chosen from (b) based on the highest GUIDE-Seq
read counts for each guide (Additional file 10: Table S3). For NmeCas9, in addition to those candidate off-target sites obtained from GUIDE-Seq (c), we
also assayed one or two potential off-target sites (designated with the “-CS” suffix) predicted by CRISPRseek as the closest near-cognate matches with
permissive PAMs. Data are mean values ± s.e.m. from three biological replicates performed on different days
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greater on-target specificity, possibly due in part to the
lower density of near-cognate sequences. As an initial step
in exploring this possibility, we used CRISPRseek [72] to
perform a global analysis of potential NmeCas9 and Spy-
Cas9 off-target sites with six or fewer mismatches in the
human genome, using sgRNAs specific for DTS3, DTS7,
and DTS8 (Fig. 4a) as representative queries. When
allowing for permissive and semi-permissive PAMs
(NGG, NGA, and NAG for SpyCas9; N4GHTT,
N4GACT, N4GAYA, and N4GTCT for NmeCas9), po-
tential off-target sites for NmeCas9 were predicted with
two to three orders of magnitude lower frequency than
for SpyCas9 (Table 2). These results hold true even
when we relaxed the PAM requirement to the “slipped”
N5GHTT, N5GACT, N5GAYA, and N5GTCT PAMs
with variant spacing (analyzed because purified, recom-
binant NmeCas9 has been observed to catalyze DNA
cleavage in vitro at such sites [52]). Furthermore, Nme-
Cas9 off-target sites with fewer than five mismatches
were rare (two sites with four mismatches) for DTS7,
and non-existent for DTS3 and DTS8 (Table 2). Even
when we relaxed the NmeCas9 PAM requirement to
N4GN3, which includes some PAMs that enable only
background levels of targeting (e.g., N4GATC (Fig. 2a)),
the vast majority of predicted off-target sites (> 96%)
for these three guides had five or more mismatches,
and none had fewer than four mismatches among the
24 nucleotides of the spacer (Fig. 4a). In contrast, the
SpyCas9 guides targeting DTS3, DTS7, and DTS8 had
49, 54, and 62 predicted off-target sites with three or
fewer mismatches, respectively, among the 20 nucleo-
tides of the spacer (Table 2). As speculated previously
[53, 54], these bioinformatic predictions suggest the
possibility that the NmeCas9 genome-editing system
may induce very few undesired mutations, or perhaps
none, even when targeting sites that induce substantial
off-targeting with SpyCas9.
Although bioinformatic predictions of off-targeting can
be useful, it is well established that off-target profiles must
be defined experimentally in a prediction-independent
fashion due to our limited understanding of target specifi-
city determinants, and the corresponding inability of algo-
rithms to predict all possible sites successfully [31, 34,
35]. The need for empirical off-target profiling is espe-
cially acute with Cas9 orthologs that are far less thor-
oughly characterized than SpyCas9. A previous report
used PCR amplification and high-throughput sequen-
cing to detect the frequencies of mutations at 15–20 pre-
dicted NmeCas9 off-target sites for each of three guides in
human cells and found only background levels of indels in
all cases, suggesting a very high degree of precision for
NmeCas9 [54]. However, this report restricted its analysis
to candidate sites with N4GNTT PAMs and three or fewer
mismatches (or two mismatches combined with a 1 nu-
cleotide bulge) in the PAM-proximal 19 nucleotides,
leaving open the possibility that legitimate off-target
sites that did not fit these specific criteria remained un-
examined. Accordingly, empirical and minimally biased
off-target profiles have never been generated for any
NmeCas9/sgRNA combination, and the true off-target
propensity of NmeCas9 therefore remains unknown. At
the time we began this work, multiple methods for
prediction-independent detection of off-target sites had
been reported including GUIDE-seq, BLESS,
Digenome-Seq, HTGTS, and IDLV capture, each with
their own advantages and disadvantages (reviewed in
[31, 34, 35]); additional methods (SITE-Seq [64],
CIRCLE-seq [73], and BLISS [74]) have been reported
more recently. Initially, we chose to apply GUIDE-seq
[63], which takes advantage of oligonucleotide incorp-
oration into double-strand break sites, for defining the
off-target profiles of both SpyCas9 and NmeCas9 when
each is programmed to edit the DTS3, DTS7, and DTS8
sites (Fig. 3c–d) in the human genome.
Table 2 Number of predicted near-cognate sites in the human genome for the three dual target sites (DTS3, DTS7 and DTS8)
analyzed in this study. These potential off-target sites differ from the on-target site by six or fewer mismatches, as listed on the left,
and include the functional or semi-functional PAMs shown at the top
Number of
mismatches
SpyCas9 sites (NGG, NGA, NAG PAMs) NmeCas9 sites (N4GATT, N4GCTT, N4GTTT,
N4GACT, N4GATA, N4GTCT, N4GACA PAMs)
NmeCas9 sites (N5GATT, N5GCTT, N5GTTT, N5GACT,
N5GATA, N5GTCT, N5GACA “slipped” PAMs)
DTS3 DTS7 DTS8 DTS3 DTS7 DTS8 DTS3 DTS7 DTS8
1 0 0 0 0 0 0 0 0 0
2 4 2 2 0 0 0 0 0 0
3 45 52 60 0 0 0 0 0 0
4 680 500 772 0 2 0 0 2 1
5 6691 4116 7325 4 5 25 0 4 12
6 45,897 26,474 52,547 17 61 129 24 62 124
Total 53,317 31,144 60,706 21 68 154 24 68 137
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After confirming that the co-transfected double-
stranded oligodeoxynucleotide (dsODN) was incorpo-
rated efficiently at the DTS3, DTS7, and DTS8 sites during
both NmeCas9 and SpyCas9 editing (Additional file 1:
Figure S4C), we then prepared GUIDE-seq libraries for
each of the six editing conditions, as well as for the negative
control conditions (i.e., in the absence of any sgRNA) for
both Cas9 orthologs. The GUIDE-seq libraries were then
subjected to high-throughput sequencing, mapped, and an-
alyzed as described [75] (Fig. 4b–c). On-target editing with
these guides was readily detected by this method, with the
number of independent reads ranging from a low of 167
(NmeCas9, DTS8) to a high of 1834 (NmeCas9, DTS3)
(Fig. 4c and Additional file 3: Table S2).
For our initial analyses, we scored candidate sites as
true off-targets if they yielded two or more independent
reads and had six or fewer mismatches with the guide,
with no constraints placed on the PAM match at that
site. For SpyCas9, two of the sgRNAs (targeting DTS3
and DTS7) induced substantial numbers of off-target
editing events (271 and 54 off-target sites, respectively
(Fig. 4b)) under these criteria. The majority of these Spy-
Cas9 off-target sites (88% and 77% for DTS3 and DTS7,
respectively) were associated with a canonical NGG
PAM. Reads were very abundant at many of these loci
and at five off-target sites (all with the DTS3 sgRNA)
even exceeded the number of on-target reads (Fig. 4c).
SpyCas9 was much more precise with the DTS8 sgRNA:
we detected a single off-target site with five mismatches
and an NGG PAM, and it was associated with only
three independent reads, far lower than the 415 reads
that we detected at the on-target site (Fig. 4c and
Additional file 3: Table S2). Overall, the range of edit-
ing accuracies that we measured empirically for Spy-
Cas9—very high (e.g., DTS8), intermediate (e.g.,
DTS7), and poor (e.g., DTS3)—are consistent with the
observations of other reports using distinct guides
(reviewed in [31, 34, 35]).
In striking contrast, GUIDE-seq analyses with Nme-
Cas9, programmed with sgRNAs targeting the exact
same three sites, yielded off-target profiles that were ex-
ceptionally specific in all cases (Fig. 4b–c). For DTS3
and DTS8, we found no reads at any site with six or
fewer guide mismatches; for DTS7, we found one
off-target site with four mismatches (three of which were
at the PAM-distal end; see Additional file 3: Table S2),
and even at this site, there were only 12 independent
reads, ~ 100× fewer than the 1222 reads detected at
DTS7 itself. This off-target site was also associated with
a PAM (N4GGCT) that would be expected to be poorly
functional, though it could also be considered a “slipped”
PAM with a more optimal consensus but variant spacing
(N5GCTT). To explore the off-targeting potential of
NmeCas9 further, we decreased the stringency of our
mapping to allow detection of off-target sites with up to
10 mismatches. Even in these conditions, only four
(DTS7), 15 (DTS8), and 16 (DTS3) candidate sites were
identified, most of which had only four or fewer reads
(Fig. 4c) and were associated with poorly functional
PAMs (Additional file 3: Table S2). We consider it likely
that most if not all of these low-probability candidate
off-target sites represent background noise caused by
spurious priming and other sources of experimental error.
As an additional test of off-targeting potential, we re-
peated the DTS7 GUIDE-seq experiments with both
SpyCas9 and NmeCas9, but this time using a different
transfection reagent (Lipofectamine3000 rather than
Polyfect). These repeat experiments revealed that > 96%
(29 out of 30) of off-target sites with up to five mis-
matches were detected under both transfection condi-
tions for SpyCas9 (Additional file 4: Table S1). However,
the NmeCas9 GUIDE-seq data showed no overlap be-
tween the potential sites identified under the two condi-
tions, again suggesting that the few off-target reads that
we did observe are unlikely to represent legitimate
off-target editing sites.
To confirm the validity of the off-target sites defined
by GUIDE-seq, we designed primers flanking candidate
off-target sites identified by GUIDE-seq, PCR-amplified
those loci following standard genome editing (i.e., in
the absence of co-transfected GUIDE-seq dsODN) (3
biological replicates), and then subjected the PCR prod-
ucts to high-throughput sequencing to detect the fre-
quencies of Cas9-induced indels. For this analysis, we
chose the top candidate off-target sites (as defined by
GUIDE-seq read count) for each of the six cases
(DTS3, DTS7, and DTS8, each edited by either SpyCas9
or NmeCas9). In addition, due to the low numbers of
off-target sites and the low off-target read counts ob-
served during the NmeCas9 GUIDE-seq experiments,
we analyzed the top two predicted off-target sites for
the three NmeCas9 sgRNAs, as identified by CRISPR-
seek (Fig. 4a and Table 2) [72]. On-target indel forma-
tion was detected in all cases, with editing efficiencies
ranging from 7% (DTS8, with both SpyCas9 and Nme-
Cas9) to 39% (DTS3 with NmeCas9) (Fig. 4d). At the
off-target sites, our targeted deep-sequencing analyses
largely confirmed our GUIDE-seq results: SpyCas9
readily induced indels at most of the tested off-target
sites when paired with the DTS3 and DTS7 sgRNAs,
and in some cases, the off-target editing efficiencies
approached those observed at the on-target sites
(Fig. 4d). Although some SpyCas9 off-targeting could
also be detected with the DTS8 sgRNA, the frequencies
were much lower (< 0.1% in all cases). Off-target edits
induced by NmeCas9 were far less frequent in all cases,
even with the DTS3 sgRNA that was so efficient at
on-target mutagenesis: many off-target sites exhibited
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editing efficiencies that were indistinguishable from
background sequencing error rates (Fig. 4d). These re-
sults, in combination with the GUIDE-seq analyses de-
scribed above, reveal wildtype NmeCas9 to be an
exceptionally precise genome-editing enzyme.
To explore NmeCas9 editing accuracy more deeply,
we used 16 NmeCas9 target sites among the 24 sites
across the genome we tested earlier, 10 with canonical
N4GATT PAMs and six with variant functional PAMs
(Additional file 5: Table S9). We then performed
GUIDE-seq analyses of NmeCas9 editing at these sites.
GUIDE-seq analysis readily revealed editing at each of
these sites, with on-target read counts ranging from ~ 100
to ~ 5000 reads (Fig. 5a) confirming the on-target editing
shown earlier by T7E1 assay and deep sequencing analyses
(Fig. 1c–e and Fig. 2b–d). Most notably, off-target reads
were undetectable by GUIDE-seq with 14 out of the 16
sgRNAs (Fig. 5b).
The two guides with off-target activity (NTS1C and
NTS25) had only two and one off-target sites, respectively
Fig. 5 Off-target analyses for additional NmeCas9 sgRNAs, targeting sites with consensus and variant PAMs. a Number of GUIDE-Seq reads for the
on-target sites, with the PAM sequences for each site indicated underneath. b Number of GUIDE-Seq-detected off-target sites using the
Bioconductor package GUIDEseq version 1.1.17 [75] with default settings except that PAM.size = 8, PAM = “NNNNGATT,” min.reads = 2,
max.mismatch = 6, allowed.mismatch.PAM= 4, PAM.pattern = “NNNNNNNN$,” BSgenomeName=Hsapiens, txdb = TxDb.Hsapiens.UCSC.hg19.knownGene,
orgAnn = org.Hs.egSYMBOL gRNA.size was set to length of the gRNA used, and various number of 0’s were added at the beginning of weights to make
the length of weights equal to the gRNA size. For example, for gRNA with length 24, weights = c(0,0,0,0,0, 0, 0.014, 0, 0, 0.395, 0.317, 0, 0.389, 0.079, 0.445,
0.508, 0.613, 0.851, 0.732, 0.828, 0.615, 0.804, 0.685, 0.583) for all sixteen sgRNAs used in (a). c Schematic diagrams of NmeCas9 sgRNA/DNA R-loops for the
NTS1C (left) and NTS25 (right) sgRNAs, at the GUIDE-Seq-detected on- and off-target sites. Black, DNA residues; boxed nts, PAM; red line, NmeCas9
cleavage site; cyan and purple, mismatch/wobble and complementary nts (respectively) in the NmeCas9 sgRNA guide region; green, NmeCas9 sgRNA
repeat nts. d NmeCas9 editing efficiencies at the NTS1C (left) and NTS25 (right) on-target sites, and at the off-target sites detected by GUIDE-Seq from (b),
as measured by PCR and high-throughput sequencing. Data are mean values ± s.e.m. from three biological replicates performed on different
days. e Comparison of NmeCas9 and SpyCas9 biochemical off-target sites using SITE-Seq analysis
Amrani et al. Genome Biology          (2018) 19:214 Page 13 of 25
(Fig. 5b and Additional file 1: Figure S11). Off-target
editing was confirmed by high-throughput sequencing
and analysis of indels (Fig. 5d). Compared with the
on-target site (perfectly matched at all positions other
than the 5′-terminal guide nucleotide, and with an opti-
mal N4GATT PAM), the efficiently targeted NTS1C-OT1
had two wobble pairs and one mismatch (all in the nine
PAM-distal nucleotides), as well as a canonical N4GATT
PAM (Fig. 5c and Additional file 3: Table S2). The
weakly edited NTS1C-OT2 site had only a single mis-
match (at the 11th nucleotide, counting in the PAM-
distal direction), but was associated with a non-canon-
ical N4GGTT (or a “slipped” N5GTTT) PAM (Fig. 5c
and Additional file 3: Table S2). NTS25 with an
N4GATA PAM was the other guide with a single
off-target site (NTS25-OT1), where NmeCas9 edited
up to ~ 1000× less efficiently than at the on-target site
(Fig. 5d). This minimal amount of off-target editing
arose despite the association of NTS25-OT1 with an
optimal N4GATT PAM, unlike the variant N4GATA
PAM that flanks the on-target site. Overall, our
GUIDE-seq and sequencing-based analyses demon-
strate that NmeCas9 genome editing is exceptionally
accurate: we detected and confirmed cellular off-target
editing with only two of the 19 guides tested, and even
in those two cases, only one or two off-target sites
could be found for each. Furthermore, of the three
bona fide off-target sites that we identified, only one
generated indels at substantial frequency (11.6%); indel
frequencies were very modest (0.3% or lower) at the
other two off-target sites.
We next sought to corroborate and expand on our
GUIDE-seq results with a second prediction-independent
method. We applied the SITE-Seq assay, a biochemical
method that does not rely on cellular events such as DNA
repair, thus potentially enabling a more thorough profiling
of genome-wide specificity [64]. SITE-Seq libraries were
prepared for the three dual target sites with both Cas9
orthologs as well as for 12 of the NmeCas9-only target
sites. SITE-Seq was performed on HEK293T genomic
DNA (gDNA) treated with a range of RNP concentrations
(4–256 nM) previously shown to discriminate high- and
low-probability cellular off-targets [64]. Finally, the result-
ing libraries were sequenced, aligned, and then analyzed
as previously described [64].
Negative controls without RNP recovered zero sites
across any concentrations, whereas SpyCas9 assembled
with sgRNAs targeting DTS3, DTS7, or DTS8 recovered
hundreds (at 4 nM RNP) to thousands (at 256 nM RNP)
of biochemical off-target sites (Fig. 5e). In contrast, Nme-
Cas9 assembled with sgRNAs targeting the same three
sites recovered only their on-target sites at 4 nM RNP and
at most 29 off-target sites at 256 nM RNP (Fig. 5e). More-
over, the 12 additional NmeCas9 target sites showed
similarly high specificity: eight samples recovered only the
on-target sites at 4 nM RNP and six of those recovered no
more than nine off-targets at 256 nMRNP (Additional file 1:
Figure S5A). Across NmeCas9 RNPs, off-target sequence
mismatches appeared enriched in the 5′ end of the sgRNA
target sequence (Additional file 6: Table S4). Finally, three
of the NmeCas9 RNPs (NTS30, NTS4C, and NTS59) re-
quired elevated concentrations to retrieve their on-targets,
potentially due to poor sgRNA transcription and/or RNP
assembly. These RNPs were therefore excluded from fur-
ther analysis.
We next performed cell-based validation experiments
to investigate whether any of the biochemical off-targets
were edited in cells. Since NmeCas9 recovered only ~ 100
biochemical off-targets across all RNPs and concentra-
tions, we could examine each site for editing in cells.
SpyCas9 generated > 10,000 biochemical off-targets across
all DTS samples, preventing comprehensive cellular pro-
filing. Therefore, for each RNP, we randomly selected 95
high cleavage sensitivity SITE-Seq sites (i.e., recovered at
all concentrations tested in SITE-Seq) for examination, as
we predicted those were more likely to accumulate edits
in cells [64] (Additional file 2: Table S5). Notably, only a
subset of the sites validated from GUIDE-seq were
contained within this list of sites (1/8 and 5/8 overlap-
ping sites for DTS3 and DTS7, respectively). SITE-Seq
and GUIDE-seq validations were performed on the
same gDNA samples to facilitate comparisons between
data sets.
Across all NmeCas9 RNPs, only three cellular off-targets
were observed. These three all belonged to the NTS1C
RNP, and two of them had also been detected previously
with GUIDE-seq. All high cleavage sensitivity SITE-Seq
sites (i.e., all on-targets and the single prominent NTS1C
off-target, NTS1C-OT1) showed editing in cells. Con-
versely, SITE-Seq sites with low cleavage sensitivity, de-
fined as being recovered at only 64 nM and/or 256 nM
RNP, were rarely found as edited (2/93 sites). Importantly,
this suggests that we identified all or the clear majority
of NmeCas9 cellular off-targets, albeit at our limit of
detection. Across all SpyCas9 RNPs, 14 cellular
off-targets were observed (8/70 sites for DTS3, 6/83 sites
for DTS7, and 0/79 sites for DTS8) [Additional file 2:
Table S5; not all 95 amplicons were included in the final
analysis as some were filtered due to low read coverage
or high variant calls in the untreated sample (see mate-
rials and methods for more details)]. Since our data set
was only a subset of the total number of high cleavage
sensitivity SITE-Seq sites and excluded many of the
GUIDE-seq validated sites, we expect that sequencing all
SITE-Seq sites may uncover additional cellular off-targets.
Taken together, these data corroborate our GUIDE-seq
results, suggesting that NmeCas9 can serve as a highly
specific genome editing platform.
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Functionality of truncated sgRNAs with NmeCas9
SpyCas9 can accommodate limited variation in the
length of the guide region (normally 20 nucleotides) of
its sgRNAs [76–79], and sgRNAs with modestly length-
ened (22-nt) or shortened (17–18-nt) guide regions can
even enhance editing specificity by reducing editing at
off-target sites by a greater degree than they affect edit-
ing at the on-target site [76, 77]. To test the length de-
pendence of the NmeCas9 guide sequence (normally 24
nucleotides [51]) during mammalian editing, we con-
structed a series of sgRNAs containing 18, 19, 20, 21, 22,
23, and 24 nucleotides of complementarity to ps9 cloned
into the split-GFP reporter plasmid (Additional file 1:
Figure S12A). All designed guides started with two guan-
ine nucleotides (resulting in 1–2 positions of target
non-complementarity at the very 5′ end of the guide) to
facilitate transcription, analogous to the SpyCas9 “GGN20”
sgRNAs [76]. We then measured the abilities of these
sgRNAs to direct NmeCas9 cleavage of the reporter in hu-
man cells. sgRNAs that have 20–23 nucleotides of target
complementarity showed activities comparable to the
sgRNA with the natural 24 nucleotides of complementar-
ity, whereas sgRNAs containing 18 or 19 nucleotides of
complementarity show lower activity (Fig. 6a).
We next used a native chromosomal target site (NTS33
in VEGFA, as in Fig. 1c–e) to test the editing efficiency of
NmeCas9 spacers of varying lengths (Additional file 1:
Figure S12B). sgRNA constructs included one or two
5′-terminal guanine residues to enable transcription by
the U6 promoter, sometimes resulting in 1–2 nucleotides
Fig. 6 NmeCas9 guide length requirements in mammalian cells. a Split-GFP activity profile of NmeCas9 cleavage with ps9 sgRNAs bearing
spacers of varying lengths (18–24 nt) along with 5′-terminal G residues to enable transcription. Bars represent mean values ± s.e.m. from three
independent biological replicates performed on different days. b T7EI analysis of editing efficiencies at the NTS33 genomic target site (with an
N4GATT PAM) with sgRNAs bearing spacers of varying lengths (13–25 nt) with 1–2 5′-terminal G residues. Products resulting from NmeCas9
genome editing are denoted by the red dots. c Quantitation of editing efficiencies (of experiment in b) from three independent biological
replicates performed on different days. Error bars indicate ± standard error of the mean (± s.e.m.). d As in (b), but targeting the NTS32 genomic
site (with a N4GCTT PAM). e Quantitation of editing efficiencies (of experiment in d) from three independent biological replicates performed on
different days. Error bars indicate ± standard error of the mean (± s.e.m.)
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of target non-complementarity at the 5′ end of the guide
sequence. sgRNAs with 20, 21, or 22 nucleotides of target
complementarity (GGN18, GGN19, and GGN20, respect-
ively) performed comparably to the natural guide length
(24 nucleotides of complementarity, GN23) at this site
(Fig. 6b–c), and within this range, the addition of 1–2 un-
paired G residues at the 5′ end had no adverse effect.
These results are consistent with the results obtained with
the GFP reporter (Fig. 6a). sgRNAs with guide lengths of
19 nucleotides or shorter, along with a single mismatch in
the first or second position (GGN17, GGN16, and GGN15),
did not direct detectable editing, nor did a sgRNA with
perfectly matched guide sequences of 17 or 14 nucleotides
(GN16 and GN13, respectively) (Fig. 6b–c). However, a
19-nt guide with no mismatches (GN18) successfully di-
rected editing. These results indicate that 19–26-nt guides
can be tolerated by NmeCas9, but that activity can be
compromised by guide truncations from the natural
length of 24 nucleotides down to 17–18 nucleotides and
smaller, and that single mismatches (even at or near the
5′-terminus of the guide) can be discriminated against
with a 19-nt guide.
The target sites tested in Fig. 6a–c are both associ-
ated with a canonical N4GATT PAM. To examine
length dependence at a site with a variant PAM, we var-
ied guide sequence length at the N4GCTT-associated
NTS32 site (also in VEGFA). In this experiment, each
of the guides had two 5′-terminal G residues, accom-
panied by 1–2 terminal mismatches with the target se-
quence (Additional file 1: Figure S12C). At the NTS32
site, sgRNAs with 21–24 nucleotides of complementar-
ity (GGN24, GGN23, GGN22, and GGN21) supported
editing, but shorter guides (GGN20, GGN19, and
GGN18) did not (Fig. 6d–e). We conclude that sgRNAs
with 20 nucleotides of complementarity can direct edit-
ing at some sites (Fig. 6b–c) but not all (Fig. 6d–e). It is
possible that this minor variation in length dependence
can be affected by the presence of mismatched 5′-ter-
minal G residues in the sgRNA, the adherence of the
target to the canonical N4GATT PAM consensus, or
both, but the consistency of any such relationship will
require functional tests at much larger numbers of
sites. Nonetheless, NmeCas9 guide truncations of 1–3
nucleotides appear to be functional in most cases, in
agreement with the results of others [54].
Truncated sgRNAs reduce off-target cleavage by
NmeCas9
Although NmeCas9 exhibits very little propensity to edit
off-target sites, for therapeutic applications, it may be de-
sirable to suppress even the small amount of off-targeting
that occurs (Fig. 5). Several strategies have been developed
to suppress off-targeting by SpyCas9 [31, 34, 35], some of
which could be readily applied to other orthologs. For
example, truncated sgRNAs (tru-sgRNAs) sometimes
suppress off-target SpyCas9 editing more than they
suppress on-target editing [77]. Because 5′-terminal
truncations are compatible with NmeCas9 function
(Fig. 6), we tested whether NmeCas9 tru-sgRNAs can
have similar suppressive effects on off-target editing
without sacrificing on-target editing efficiency.
First, we tested whether guide truncation can lead to
NmeCas9 editing at novel off-target sites (i.e., at off-target
sites not edited by full-length guides), as reported previ-
ously for SpyCas9 [77]. Our earlier tests of NmeCas9
on-target editing with tru-sgRNAs used guides targeting
the NTS33 (Fig. 6b–c) and NTS32 (Fig. 6d–e) sites. We
again used GUIDE-seq with a subset of the validated
NTS32 and NTS33 tru-sgRNAs to determine whether
NmeCas9 guide truncation leads to off-target editing at
new sites, and found none (Additional file 1: Figure S13).
Although we cannot rule out the possibility that other
NmeCas9 guides could be identified that yield novel
off-target events upon truncation, our results suggest that
de novo off-targeting by NmeCas9 tru-sgRNAs is unlikely
to be a pervasive problem.
The most efficiently edited off-target site from our
previous analyses was NTS1C-OT1, providing us with
our most stringent test of off-target suppression. When
targeted by the NTS1C sgRNA, NTS1C-OT1 has one
rG-dT wobble pair at position − 16 (i.e., at the 16th base
pair from the PAM-proximal end of the R-loop), one
rC-dC mismatch at position − 19, and one rU-dG wob-
ble pair at position − 23 (Fig. 5c). We generated a series
of NTS1C-targeting sgRNAs with a single 5′-terminal G
(for U6 promoter transcription) and spacer complemen-
tarities ranging from 24 to 15 nucleotides (GN24 to
GN15, Additional file 1: Figure S14A, top panel). Con-
versely, we designed a similar series of sgRNAs with per-
fect complementarity to NTS1C-OT1 (Additional file 1:
Figure S14B, top panel). Consistent with our earlier re-
sults with other target sites (Fig. 6), T7E1 analyses re-
vealed that both sets of guides enabled editing of the
perfectly-matched on-target site with truncations down
to 19 nucleotides (GN18), but that shorter guides were
inactive. On-target editing efficiencies at both sites were
comparable across the seven active guide lengths (GN24
through GN18), with the exception of slightly lower
efficiencies with the GN19 guides (Additional file 1:
Figure S14A & B, middle and bottom panels).
We then used targeted deep sequencing to test
whether off-target editing is reduced with the truncated
sgRNAs. With both sets of sgRNAs (perfectly comple-
mentary to either NTS1C or NTS1C-OT1), we found
that off-targeting at the corresponding near-cognate site
persisted with the four longest guides (GN24, GN23,
GN22, GN21; Fig. 7). However, off-targeting was abol-
ished with the GN20 guide, without any significant
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reduction in on-target editing efficiencies (Fig. 7).
Off-targeting was also absent with the GN19 guide, though
on-target editing efficiency was compromised. These re-
sults, albeit from a limited data set, indicate that truncated
sgRNAs (especially those with 20 or 19 base pairs of
guide/target complementarity, 4–5 base pairs fewer than
the natural length) can suppress even the limited degree
of off-targeting that occurs with NmeCas9.
Unexpectedly, even though off-targeting at NTS1C-
OT1 was abolished with the GN20 and GN19 truncated
NTS1C sgRNAs, truncating by an additional nucleotide
(to generate the GN18 sgRNA) once again yielded
NTS1C-OT1 edits (Fig. 7a). This could be explained by
the extra G residue at the 5′-terminus of each sgRNA in
the truncation series (Additional file 1: Figure S14). With
the NTS1C GN19 sgRNA, both the 5′-terminal G resi-
due and the adjacent C residue are mismatched with the
NTS1C-OT1 site. In contrast, with the GN18 sgRNA,
the 5′-terminal G is complementary to the off-target site.
In other words, with the NTS1C GN19 and GN18 sgRNAs,
the NTS1C-OT1 off-target interactions (which are identi-
cal in the PAM-proximal 17 nucleotides) include two add-
itional nucleotides of non-complementarity or one
additional nucleotide of complementarity, respectively.
Thus, the more extensively truncated GN18 sgRNA has
greater complementarity with the NTS1C-OT1 site than
the GN19 sgRNA, explaining the re-emergence of
off-target editing with the former. This observation high-
lights the fact that the inclusion of a 5′-terminal G residue
that is mismatched with the on-target site, but that is
complementary to a C residue at an off-target site, can
limit the effectiveness of a truncated guide at suppressing
off-target editing, necessitating care in truncated sgRNA
design when the sgRNA is generated by cellular transcrip-
tion. This issue is not a concern with sgRNAs that are
generated by other means (e.g., chemical synthesis) that
do not require a 5′-terminal G. Overall, our results dem-
onstrate that NmeCas9 genome editing is exceptionally
precise, and even when rare off-target editing events
occur, tru-sgRNAs can provide a simple and effective way
to suppress them.
Discussion
The ability to use type II and type V CRISPR-Cas
systems as RNA-programmable DNA-cleaving systems
[13, 14, 27] is revolutionizing many aspects of the life
sciences and holds similar promise for biotechnological,
agricultural, and clinical applications. Most applications
reported thus far have used a single Cas9 ortholog (Spy-
Cas9). Thousands of additional Cas9 orthologs have also
been identified [28], but only a few have been character-
ized, validated for genome engineering applications, or
both. The development of additional orthologs promises
to increase the number of targetable sites (through new
PAM specificities), extend multiplexing possibilities (for
pairwise combinations of Cas9 orthologs with orthog-
onal guides), and improve deliverability (for the more
compact Cas9 orthologs). In addition, some Cas9s may
show mechanistic distinctions (such as staggered vs.
blunt dsDNA breaks) [80], greater protein stability in
vivo, improved control mechanisms (e.g., via multiple
anti-CRISPRs that act at various stages of the DNA
cleavage pathway) [57, 58, 60, 61, 81–83], and other en-
hancements. Finally, some may exhibit a greater natural
propensity to distinguish between on- vs. off-target sites
during genome editing applications, obviating the need
Fig. 7 Guide truncation can suppress off-target editing by NmeCas9. a Editing efficiencies at the NTS1C (on-target, red) and NTS1C-OT1 (off-target,
orange) genomic sites, after editing by NmeCas9 and NTS1C sgRNAs of varying lengths, as measured by PCR and high-throughput sequencing. Data
are mean values ± s.e.m. from three biological replicates performed on different days. b As in (a), but using sgRNAs perfectly complementary to the
NTS1C-OT1 genomic site. Two-tailed paired Student’s T test showed significant difference in on- and off-target editing efficiency as a function of guide
truncation. On-target editing (black asterisk) or off-target editing (red asterisk) is compared to the baseline condition GN24, respectively (p < 0.05 is
annotated with one asterisk; p < 0.01 is annotated with two asterisks)
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for extensive engineering (as was necessary with SpyCas9)
to attain the accuracy needed for many applications, espe-
cially therapeutic development.
Here we have further defined the properties of NmeCas9
during editing in human cells, including validation and ex-
tension of previous analyses of guide length and PAM re-
quirements [46, 53, 54]. Intriguingly, the tolerance to
deviations from the N4G(A/C)TT natural PAM consensus
[51] observed in vitro and in bacterial cells [46, 52] is con-
siderably reduced in the mammalian context, i.e., fewer
PAM variations are permitted during mammalian editing.
The basis for this context-dependent difference is not clear
but may be due in part to the ability to access targets within
eukaryotic chromatin, or to the larger numbers of PAMs
that must be scanned (due to the much larger genome sizes
in mammalian cells), since lower SpyCas9/sgRNA concen-
trations (relative to potential DNA substrates) have been
shown to improve accuracy [30, 84, 85]. We have also
found that steady-state NmeCas9 levels in human cells are
markedly increased in the presence of its cognate sgRNA,
suggesting that sgRNA-loaded NmeCas9 is more stable
than apo NmeCas9. An increased proteolytic sensitivity
of apo Cas9 relative to the sgRNA-bound form has
been noted previously for a different type II-C ortholog
(CdiCas9 [55]).
A previous report indicated that NmeCas9 has high in-
trinsic accuracy, based on analyses of candidate off-target
sites that were predicted bioinformatically [54]. However,
the true genome-wide accuracy of NmeCas9 was not
assessed empirically, as is necessary given well-established
imperfections in bioinformatic predictions of off-targeting
[31, 34, 35]. We have used GUIDE-seq [63] and SITE-Seq
[64] to define the genome-wide accuracy of wildtype
NmeCas9, including side-by-side comparisons with wild-
type SpyCas9 during editing of identical on-target sites.
We find that NmeCas9 is a consistently high-accuracy
genome editor, with off-target editing undetectable above
background with 17 out of 19 analyzed sgRNAs, and only
one or three verified off-target edits with the remaining
two guides. We observed this exquisite specificity by
NmeCas9 even with sgRNAs that target sites (DTS3 and
DTS7 (see Fig. 4)) that are highly prone to off-target edit-
ing when targeted with SpyCas9. Of the four off-target
sites that we validated, three accumulated < 1% indels.
Even with the one sgRNA that yielded a significant fre-
quency of off-target editing (NTS1C, which induced
indels at NTS1C-OT1 with approximately half the effi-
ciency of on-target editing), the off-targeting with
wildtype NmeCas9 could be easily suppressed with
truncated sgRNAs. Our ability to detect NTS25-OT1
editing with GUIDE-seq, despite its very low (0.06%)
editing efficiency based on high-throughput sequen-
cing, indicates that our GUIDE-seq experiments can
identify even very low-efficiency off-target editing sites.
Similar considerations apply to our SITE-Seq analyses.
We observed high accuracy even when NmeCas9 is de-
livered by plasmid transfection, a delivery method that
is associated with higher off-target editing than more
transient delivery modes such as RNP delivery [86, 87].
Low off-target activity even with sustained effector ex-
pression could be particularly useful for AAV delivery,
as recently validated for NmeCas9 [88].
The two type II-C Cas9 orthologs (NmeCas9 and
CjeCas9) that have been validated for mammalian gen-
ome editing and assessed for genome-wide specificity
[47, 54] (this work) and both have proven to be naturally
hyper-accurate. Both use longer guide sequences than
the 20-nucleotide guides employed by SpyCas9, and
both also have longer and more restrictive PAM require-
ments. For both type II-C orthologs, it is not yet known
whether the longer PAMs, longer guides, or both ac-
count for the limited off-target editing. Type II-C Cas9
orthologs generally cleave dsDNA more slowly than Spy-
Cas9 [49, 55], and it has been noted that lowering kcat
can, in some circumstances, enhance specificity [89]. In
keeping with the generally lower enzymatic activity, a re-
cent report found NmeCas9 to exhibit consistently lower
cellular editing activity than the two type II-A Cas9s
tested (SpyCas9 and SauCas9), though most tests in that
report were done with suboptimal guide lengths for
NmeCas9 [90]. Whatever the mechanistic basis for the
high intrinsic accuracy, it is noteworthy that it is a prop-
erty of the native proteins, without a requirement for ex-
tensive engineering. This adds to the motivation to
identify more Cas9 orthologs with human genome-editing
activity, as it suggests that it may be unnecessary in many
cases (perhaps especially among type II-C enzymes) to in-
vest heavily in structural and mechanistic analyses and en-
gineering efforts to attain sufficient accuracy for many
applications and with many desired guides, as was done
with (for example) SpyCas9 [32, 33, 37, 38, 65]. Although
Cas9 orthologs with more restrictive PAM requirements
(such as NmeCas9, CjeCas9, and GeoCas9) by definition
will afford lower densities of potential target sites than
SpyCas9 (which also usually affords the highest on-tar-
get editing efficiencies among established Cas9 ortho-
logs), the combined targeting possibilities for multiple
such Cas9s will increase the targeting options available
within a desired sequence window, with little propen-
sity for off-targeting. The continued exploration of nat-
ural Cas9 variation, especially for those orthologs with
other advantages such as small size and anti-CRISPR
off-switch control, therefore has great potential to advance
the CRISPR genome editing revolution.
Conclusions
NmeCas9 is an intrinsically high-accuracy genome-edit-
ing enzyme in mammalian cells, and the limited
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off-target editing that occurs can (at least in some cases)
be suppressed by guide truncation. Continued explor-
ation of Cas9 orthologs could therefore yield additional
enzymes that do not require extensive characterization
and engineering to prevent off-target editing.
Methods
Plasmids
Two plasmids for the expression of NmeCas9 were used
in this study. The first construct (used in Figs. 1, 2, 6
and 7) was derived from the plasmid pSimpleII where
NmeCas9 was cloned under the control of the elong-
ation factor-1α promoter, as described previously [53].
The Cas9 gene in this construct expresses a protein
with two NLSs and an HA tag. To make an
all-in-one expression plasmid, a fragment containing a
BsmBI-crRNA cassette linked to the tracrRNA by six
nucleotides, under the control of U6 RNA polymerase
III promoter, was synthesized as a gene block (Integrated
DNA Technologies) and inserted into pSimpleII, generat-
ing the pSimpleII-Cas9-sgRNA-BsmBI plasmid that in-
cludes all elements needed for editing (Addgene #115694).
To insert specific spacer sequence into the crRNA cas-
sette, synthetic oligonucleotides were annealed to generate
a duplex with overhangs compatible with those generated
by BsmBI digestion of the pSimpleII-Cas9-sgRNA-BsmBI
plasmid. The insert was then ligated into the BsmBI-di-
gested plasmid. For Figs. 3 and 4, NmeCas9 (Addgene
#87448) and SpyCas9 (Addgene #69220) constructs were
expressed from the pCS2-Dest Gateway plasmid under
the control of the CMV IE94 promoter [91]. All sgRNAs
used with pCS2-Dest-Cas9 were driven by the U6 pro-
moter in pLKO.1-puro (Addgene #52628 and #86195) [62].
The M427 GFP reporter plasmid [66] was used as
described [65].
Cell culture, transfection, and transduction
HEK293T were cultured in DMEM with 10% FBS and
1% Penicillin/Streptomycin (Gibco) in a 37 °C incubator
with 5% CO2. K562 cells were grown in the same condi-
tions but using IMDM. HFF cells were grown in the
same conditions but using DMEM with Glutamax and
20% FBS without antibiotics. mESCs were grown in
DMEM supplemented with 10% FBS, glutamine beta-ME
and LIF. For transient transfection, we used early to
mid-passage cells (passage number 4–18). Approximately
1.5 × 105 cells were transfected with 150 ng Cas9-express-
ing plasmid, 150 ng sgRNA-expressing plasmid and 10 ng
mCherry plasmid using Polyfect transfection reagent
(Qiagen) in a 24-well plate according to the manufac-
turer’s protocol. For the GFP reporter assay, 100 ngM427
plasmid was included in the co-transfection mix. Trans-
duction was done as described previously [92].
Western blotting
Forty-eight hours after transfection, cells were har-
vested and lysed with 50 μl of RIPA buffer. Protein con-
centration was determined with the BCA kit (Thermo
Scientific), and 12 μg of proteins were used for electro-
phoresis and blotting. The blots were probed with
anti-HA (Sigma, H3663) and anti-GAPDH (Abcam,
ab9485) as primary antibodies, and then with horseradish
peroxidase-conjugated anti-mouse IgG (Thermoscien-
tific, 62-6520) or anti-rabbit IgG (Biorad, 1706515)
secondary antibodies, respectively. Blots were visual-
ized using the Clarity Western ECL substrate (Biorad,
170-5060).
Flow cytometry
The GFP reporter was used as described previously [65].
Briefly, cells were harvested 48 h after transfection and used
for FACS analysis (BD Accuri 6C). To minimize the effects
of differences in the efficiency of transfection among sam-
ples, cells were initially gated for mCherry-expression, and
the percentage of GFP-expressing cells were quantified
within mCherry positive cells. All experiments were per-
formed in triplicate with data reported as mean values with
error bars indicating the standard error of the mean
(s.e.m.).
Genome editing
Seventy-two hours after transfection, genomic DNA was
extracted via the DNeasy Blood and Tissue kit (Qiagen),
according to the manufacturer’s protocol. Fifty-nanogram
DNA was used for PCR amplification using primers
specific for each genomic site (Additional file 5: Table
S9) with High Fidelity 2X PCR Master Mix (New
England Biolabs). For T7E1 analysis, 10 μl of PCR
product was hybridized and treated with 0.5 μl T7
Endonuclease I (10 U/μl, New England Biolabs) in 1X
NEB Buffer 2 for 1 h. Samples were run on a 2.5%
agarose gel, stained with SYBR-safe (ThermoFisher
Scientific), and quantified using the ImageMaster-TotalLab
program. Indel percentages are calculated as previously
described [93, 94]. Experiments for T7E1 analysis are
performed in triplicate with data reported as mean ± s.e.m.
For indel analysis by TIDE, 20 ng of PCR product is
purified and then sequenced by Sanger sequencing.
The trace files were subjected to analysis using the
TIDE web tool (https://tide.deskgen.com).
Expression and purification of NmeCas9
NmeCas9 was cloned into the pMCSG7 vector contain-
ing a T7 promoter followed by a 6XHis tag and a to-
bacco etch virus (TEV) protease cleavage site. Two
NLSs on the C-terminus of NmeCas9 and another NLS
on the N-terminus were also incorporated (Addgene
#120078). This construct was transformed into the
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Rosetta 2 DE3 strain of E. coli. Expression of NmeCas9
was performed as previously described for SpyCas9 [14].
Briefly, a bacterial culture was grown at 37 °C until an
OD600 of 0.6 was reached. At this point, the temperature
was lowered to 18 °C followed by addition of 1mM Isopro-
pyl β-D-1-thiogalactopyranoside (IPTG) to induce protein
expression. Cells were grown overnight and then harvested
for purification. Purification of NmeCas9 was per-
formed in three steps: Nickel affinity chromatography,
cation exchange chromatography, and size exclusion
chromatography. The detailed protocols for these can
be found in [14].
RNP delivery of NmeCas9
RNP delivery of NmeCas9 was performed using the
Neon transfection system (ThermoFisher). Approxi-
mately 40 picomoles of NmeCas9 and 50 picomoles of
sgRNA (transcribed from PCR-assembled templates in
vitro with T7 RNA polymerase) were mixed in buffer R
and incubated at room temperature for 30 min. This
preassembled complex was then mixed with 50,000–
150,000 cells, and electroporated using 10 μL Neon
tips. After electroporation, cells were plated in pre-
warmed 24-well plates containing the appropriate cul-
ture media without antibiotics. The number of cells
used and pulse parameters of electroporation were
different for different cell types tested. The number of
cells used was 50,000, 100,000, and 150,000 for
PLB985 cells, HEK293T cells, and K562/HFF cells re-
spectively. Electroporation parameters (voltage, width,
number of pulses) were 1150 v, 20 ms, 2 pulses for
HEK293T cells; 1000 v, 50 ms, 1 pulse for K562 cells;
1350 v, 35ms, 1 pulse for PLB985 cells; and 1700 v, 20ms,
1pulse for HFF cells.
γH2AX immunofluorescence staining and flow cytometry
For immunofluorescence, mouse embryonic stem cells
(mESCs) were crosslinked with 4% paraformaldehyde
and stained with anti-γH2AX (LP BIO, AR-0149-200) as
primary antibody and Alexa Fluor® 488 goat anti-rabbit
IgG (Invitrogen, A11034) as secondary antibody. DNA
was stained with DAPI. For a positive control, E14 cells
were irradiated with 254 nm UV light (3 mJ/cm2). Im-
ages were taken by a Nikon Eclipse E400 and representa-
tive examples were chosen.
For flow cytometry, cells were fixed with 70% ethanol,
primary and secondary antibody were as described above
for immunofluorescence, and DNA was stained with pro-
pidium iodide. Cells were analyzed by BD FACSCalibur.
The box plot was presented with the bottom line of the
box representing the first quartile, the band inside box in-
dicating the median, the top line being the third quartile,
the bottom end of whisker denoting data of first quartile
minus 1.5 times of interquartile range (no less than 0),
and the top end of the whisker indicating data of
third quartile plus 1.5 times of interquartile. Outliers
are not shown. All experiments were performed in
duplicate. For genotoxicity assay in HEK293T cells,
we treated positive control cells with 5 mJ/cm2 UV ir-
radiation. We used the same protocol described above
for antibody staining. Cells were analyzed by MACS-
Quant flow cytometer. Two independent experiments
were performed on different days.
CRISPRseek analysis of potential off-target sites
Global off-target analyses for DTS3, DTS7, and DTS8
with NmeCas9 sgRNAs were performed using the Bio-
conductor package CRISPRseek 1.9.1 [72] with parameter
settings tailored for NmeCas9. Specifically, all parameters
are set as default except the following: gRNA.size = 24,
PAM = “NNNNGATT,” PAM.size = 8, RNA.PAM.pattern =
“NNNNGNNN$” (or “NNNNNGNNN$” for slipped PAM
prediction), weights = c(0, 0, 0, 0, 0, 0, 0.014, 0, 0, 0.395,
0.317, 0, 0.389, 0.079, 0.445, 0.508, 0.613, 0.851, 0.732,
0.828, 0.615, 0.804, 0.685, 0.583), max.mismatch = 6,
allowed.mismatch.PAM=7, topN= 10,000, min.score = 0.
This setting means that all seven permissive PAM sequences
(N4GATT, N4GCTT, N4GTTT, N4GACA, N4GACT,
N4GATA, N4GTCT) were allowed and all off-targets with
up to 6 mismatches were collected [the sgRNA length was
changed from 20 to 24; four additional zeros were added to
the beginning of the weights series to be consistent with the
gRNA length of 24; and topN (the number of off-target sites
displayed) and min.score (the minimum score of an
off-target to be included in the output) were modified to
enable identification of all off-target sites with up to 6
mismatches]. Predicted off-target sites for DTS3, DTS7, and
DTS8 with SpyCas9 sgRNAs were obtained using
CRISPRseek 1.9.1 default settings for SpyCas9 (with
NGG, NAG, and NGA PAMs allowed). Batch scripts
for high-performance computing running the IBM LSF
scheduling software are included in the supplemental
section. Off-target sites were binned according to the
number of mismatches relative to the on-target se-
quence. The numbers of off-targets for each sgRNA
were counted and plotted.
GUIDE-seq
We performed GUIDE-seq experiment with some modifi-
cations to the original protocol [63], as described [65].
Briefly, in 24-well format, HEK293T cells were transfected
with 150 ng of Cas9, 150 ng of sgRNA, and 7.5 pmol of
annealed GUIDE-seq oligonucleotide using Polyfect trans-
fection reagent (Qiagen) for all six guides (DTS3, DTS7,
and DTS8 for both the NmeCas9 and SpyCas9 systems).
Experiments with DTS7 sgRNAs were repeated using Lipo-
fectamine 3000 transfection reagent (Invitrogen) according
to the manufacturer’s protocol. Forty-eight hours after
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transfection, genomic DNA was extracted with a DNeasy
Blood and Tissue kit (Qiagen) according to the manufac-
turer’s protocol. Library preparation (Additional file 7: Table
S6), sequencing, and read analyses were done according to
protocols described previously [63, 65]. Only sites that har-
bored a sequence with up to six or ten mismatches with
the target site (for SpyCas9 or NmeCas9, respectively) were
considered potential off-target sites. Data were analyzed
using the Bioconductor package GUIDEseq version 1.1.17
(Zhu et al., 2017). For SpyCas9, default setting was used
except that min.reads = 2, max.mismatch = 6, allowed.
mismatch.PAM = 2, PAM.pattern = “NNN$,” BSgenome
Name = Hsapiens, txdb = TxDb.Hsapiens.UCSC.hg19.
knownGene, orgAnn = org.Hs.egSYMBOL For NmeCas9,
default setting was used except that PAM.size = 8, PAM
= “NNNNGATT,” min.reads = 2, allowed.mismatch.PAM
= 4, PAM.pattern = “NNNNNNNN$,” BSgenomeName =
Hsapiens, txdb = TxDb.Hsapiens.UCSC.hg19.knownGene,
orgAnn = org.Hs.egSYMBOL. NmeCas9 dataset was ana-
lyzed twice with max.mismatch = 6 and max.mismatch =
10 respectively. The gRNA.size was set to the length of
the gRNA used, and various number of 0’s was added at
the beginning of weights to make the length of weights
equal to the gRNA size. For example, for gRNA with
length 24, weights = c(0,0,0,0,0, 0, 0.014, 0, 0, 0.395, 0.317,
0, 0.389, 0.079, 0.445, 0.508, 0.613, 0.851, 0.732, 0.828,
0.615, 0.804, 0.685, 0.583) (Zhu et al., 2017). These regions
are reported in Additional file 3: Table S2.
SITE-Seq
We performed the SITE-Seq assay as described previously
[64]. In 50-mL conical tubes, high molecular weight gen-
omic DNA (gDNA) was extracted from HEK293T cells
using the Blood and Cell Culture DNA Maxi Kit (Qiagen)
according to the manufacturer’s protocol. sgRNAs for
both NmeCas9 and SpyCas9 RNP assembly were tran-
scribed from PCR-assembled DNA templates containing
T7 promoters. Oligo sequences used in DNA template
assembly can be found in Additional file 8: Table S8. PCR
reactions were performed using Q5 Hot Start High-Fidel-
ity 2X Master Mix (New England Biolabs) with the follow-
ing thermal cycling conditions: 98 °C for 2min, 30 cycles
of 20 s at 98 °C, 20 s at 52 °C, 15 s at 72 °C, and a final
extension at 72 °C for 2min. sgRNAs were in vitro tran-
scribed using the HiScribe T7 High Yield RNA Synthesis
Kit (New England Biolabs) according to the manufac-
turer’s protocol. Transcription reactions were digested
with 2 units RNase-free DNase I (New England Biolabs) at
37 °C for 10min; the reaction was stopped by adding
EDTA to a final concentration of 35mM and incubating
at 75 °C for 10min. All guides were purified with RNA-
Clean beads (Beckman Coulter) and quantified with the
Quant-IT Ribogreen RNA Assay kit (ThermoFisher) ac-
cording to the manufacturers’ protocols.
Individual RNPs were prepared by incubating each
sgRNA at 95 °C for 2 min, then allowed to slowly come
to room temperature over 5 min. Each sgRNA was then
combined with its respective Cas9 in a 3:1 sgRNA:Cas9
molar ratio and incubated at 37 °C for 10 min in cleavage
reaction buffer (20 mM HEPES, pH 7.4, 150 mM KCl,
10 mM MgCl2, 5% glycerol). In 96-well format, 10 μg of
gDNA was treated with 0.2 pmol, 0.8 pmol, 3.2 pmol,
and 12.8 pmol of each RNP in 50 μL total volume in
cleavage reaction buffer, in triplicate. Negative control
reactions were assembled in parallel and did not include
any RNP. gDNA was treated with RNPs for 4 h at 37 °C.
Library preparation and sequencing were done according
to protocols described previously [64] using the Illumina
NextSeq platform, and ~ 3 million reads were obtained
for each sample. Any SITE-Seq sites without off-target
motifs located within 1 nt of the cut-site were considered
false-positives and discarded.
Targeted deep sequencing analysis
To measure indel frequencies, targeted deep sequencing
analyses were done as previously described [65]. Briefly, we
used two-step PCR amplification to produce DNA frag-
ments for each on-target and off-target site. In the first step,
we used locus-specific primers bearing universal overhangs
with complementary ends to the TruSeq adaptor sequences
(Additional file 9: Table S7). DNA was amplified with
Phusion High Fidelity DNA Polymerase (New England
Biolabs) using annealing temperatures of 60 °C, 64 °C or
68 °C, depending on the primer pair. In the second step,
the purified PCR products were amplified with a uni-
versal forward primer and an indexed reverse primer to
reconstitute the TruSeq adaptors (Additional file 9:
Table S7). Input DNA was PCR-amplified with Phusion
High Fidelity DNA Polymerase (98 °C, 15 s; 61 °C, 25 s;
72 °C, 18 s; 9 cycles), and equal amounts of the products
from each treatment group were mixed and run on a 2.5%
agarose gel. Full-size products (~ 250 bp in length) were
gel-extracted. The purified library was deep sequenced
using a paired-end 150 bp MiSeq run.
MiSeq data analysis was performed using a suite of
Unix-based software tools. First, the quality of paired-end
sequencing reads (R1 and R2 fastq files) was assessed
using FastQC (http://www.bioinformatics.babraham.ac.uk/
projects/fastqc/). Raw paired-end reads were combined
using paired end read merger (PEAR) [95] to generate sin-
gle merged high-quality full-length reads. Reads were then
filtered by quality [using Filter FASTQ [96]] to remove
those with a mean PHRED quality score under 30 and a
minimum per base score under 24. Each group of reads
was then aligned to a corresponding reference sequence
using BWA (version 0.7.5) and SAMtools (version 0.1.19).
To determine indel frequency, size, and distribution, all
edited reads from each experimental replicate were
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combined and aligned, as described above. Indel types and
frequencies were then cataloged in a text output format
at each base using bam-readcount (https://github.com/
genome/bam-readcount). For each treatment group, the
average background indel frequencies (based on indel
type, position, and frequency) of the triplicate negative
control group were subtracted to obtain the nuclease-
dependent indel frequencies. Indels at each base were
marked, summarized, and plotted using GraphPad Prism.
Deep sequencing data and the results of statistical tests are
reported in Additional file 10: Table S3.
SITE-Seq cell-based validation was performed as pre-
viously described with minor modifications [64]. In brief,
SITE-Seq sites were amplified from ~ 1000 to 4000 tem-
plate copies per replicate and sequencing data from
Cas9-treated samples were combined to minimize any
variability due to uneven coverage across replicates. Cas9
cleavage sites were registered from the SITE-Seq data, and
mutant reads were defined as any non-reference variant
calls within 20 bp of the cut site. Sites with low sequencing
coverage (< 1000 reads in the combined, Cas9-treated
samples or < 200 reads in the reference samples) or > 2%
variant calls in the reference samples were discarded. Sites
were tallied as cellular off-targets if they accumulated
> 0.5% mutant reads in the combined, Cas9-treated
samples. This threshold corresponded to sites that
showed unambiguous editing when DNA repair pat-
terns were visually inspected.
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